Results 181 to 190 of about 10,082 (205)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Clinical Pharmacokinetics, 2016
Eric Zijlstra, Ulrike Hövelmann, Tim Heise   +2 more
exaly  

Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes*

Journal of Diabetes, 2016
Gregory R Fulcher, Søren Rasmussen, Jens Sandahl Christiansen   +2 more
exaly  

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Diabetes Technology and Therapeutics, 2020
Viral Shah, Bhaswati Mukherjee, Satish K Garg   +2 more
exaly  

DDB (aspartic, aspartic, glutamic acids)

2008
openaire   +1 more source

Aspartic Acid: Aspartate, Asp, D

2013
openaire   +1 more source

Is Aspartate Aminotransferase Enough?

American Journal of Gastroenterology, 2000
GIANNINI, EDOARDO GIOVANNI, TESTA, ROBERTO   +1 more
openaire   +2 more sources

Pharmacological Properties of Faster-Acting Insulin Aspart

Current Diabetes Reports, 2017
Torben Biester, Olga Kordonouri, Thomas Danne   +2 more
exaly  

ASPARTIC PROTEASES

2018
ALMEIDA CARLA SOFIA GOMES MALAQUIAS DE, SIMÕES ISAURA ISABEL GONÇALVES, FARO CARLOS JOSE FIALHO COSTA   +2 more
openaire   +3 more sources

ASPARTIC ACID AND CANCER

The Lancet, 1968
B, Szende, E, Tyihák
openaire   +2 more sources

Aspartate

2003
openaire   +1 more source